COZADD BRUCE C sold $16.2M of JAZZ
COZADD BRUCE C sold 68,808 shares of Jazz Pharmaceuticals plc (JAZZ) at an average of $235.95 ($234.91–$237.39, $16.24M total) across 4 trades on 2026-11-06.
How this was made
The 30-second read
Why it matters
The director's sale reduces insider ownership, which can be interpreted as a negative signal by the market.
Market read
The insider sale provides fresh material that may influence short-term trading decisions on JAZZ.
What to watch
No 10b5-1 plan was in place, suggesting the sale was discretionary.
Background
SEC Form 4 filing discloses insider transactions; such filings are closely watched for potential signals.
Ticker impact
Director Cozadd Bruce C sold 68,808 shares for $16.2M, reducing his stake to 357,567 shares.
likely downward pressure as market prices in the insider sale
Form 4 filing is a primary source; the $16M sale by a director is material and new information.
Market effects
May affect perception of the biotech/pharma sector if insider sells are viewed as a broader signal.
Limited to U.S. markets where Jazz Pharma trades.
Minimal global impact beyond investors in JAZZ.
Counterpoint
The sale could be a routine portfolio rebalancing unrelated to company fundamentals.
Key entities
- CompanyJazz Pharmaceuticals plc
NASDAQ-listed biopharmaceutical company.
- IndividualCozadd Bruce C
Director of Jazz Pharmaceuticals.
